Form 4: Apellis CMO Sells Shares for Tax Withholding

Apellis Pharmaceuticals' Chief Medical Officer, Caroline Baumal, sold 3,020 shares of common stock to cover tax obligations related to restricted stock unit vesting.

Summary

• Caroline Baumal, Chief Medical Officer of Apellis Pharmaceuticals, Inc. (APLS), reported a sale of common stock.
• The transaction involved the disposition of 3,020 shares of Apellis common stock.
• The shares were sold at a price of $25.5287 per share.
• The sale occurred on January 5, 2026, and was made to cover tax withholding obligations on Restricted Stock Units (RSUs) that vested on January 3, 2026.
• Following this transaction, Caroline Baumal beneficially owns 91,206 shares of Apellis common stock.
• The reported beneficial ownership includes 925 shares acquired from an Employee Stock Purchase Plan (ESPP) on October 31, 2025.
• The transaction was made pursuant to a Rule 10b5-1 plan, indicating a pre-arranged sale.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine, non-discretionary sale to cover tax obligations on vested equity, rather than a discretionary sale indicating a change in management's outlook on the company's prospects.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This is a routine insider transaction related to compensation and tax obligations, which is common across all industries for executives receiving equity-based compensation. It does not reflect broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: Minimal impact, as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in the insider's view of the company's value.
• Employees: No direct impact.

Key Dates

Recommendation

The transaction is a non-discretionary sale to cover tax liabilities associated with the vesting of Restricted Stock Units. Such sales are a common and expected part of executive compensation and do not typically reflect a change in the insider's confidence in the company's future performance. Therefore, this filing alone does not warrant a change in investment recommendation; a 'hold' stance is maintained based on the neutral nature of this specific event.

Keywords

Apellis Pharmaceuticals, APLS, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, Caroline Baumal, Chief Medical Officer, Rule 10b5-1